SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020 Read more about SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020 SIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results Read more about SIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results SIGA Announces Award of First International Contract for Oral TPOXX® with Purchase by the Canadian Department of National Defence Read more about SIGA Announces Award of First International Contract for Oral TPOXX® with Purchase by the Canadian Department of National Defence SIGA Technologies, Inc. Reports Financial Results for Fiscal Year 2019 Read more about SIGA Technologies, Inc. Reports Financial Results for Fiscal Year 2019 SIGA Announces Collaboration with Turnstone Biologics Read more about SIGA Announces Collaboration with Turnstone Biologics SIGA to Host Business Update Call on March 5, 2020 after Release of Year End Financial Results Read more about SIGA to Host Business Update Call on March 5, 2020 after Release of Year End Financial Results SIGA Announces Canadian Department of National Defence Intent to Purchase Up To 15,325 Courses of Oral TPOXX® Read more about SIGA Announces Canadian Department of National Defence Intent to Purchase Up To 15,325 Courses of Oral TPOXX® SIGA Announces Canadian Release of the Advanced Contract Award Notice to Support Regulatory Filing for Oral TPOXX® Read more about SIGA Announces Canadian Release of the Advanced Contract Award Notice to Support Regulatory Filing for Oral TPOXX® SIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019 Read more about SIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019 SIGA Completes Clinical Studies for IV Formulation of TPOXX®, NDA to be Submitted in 2020 Read more about SIGA Completes Clinical Studies for IV Formulation of TPOXX®, NDA to be Submitted in 2020 Pagination First page « First Previous page ‹ Previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page Next › Last page Last » Subscribe to
SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020 Read more about SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020
SIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results Read more about SIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results
SIGA Announces Award of First International Contract for Oral TPOXX® with Purchase by the Canadian Department of National Defence Read more about SIGA Announces Award of First International Contract for Oral TPOXX® with Purchase by the Canadian Department of National Defence
SIGA Technologies, Inc. Reports Financial Results for Fiscal Year 2019 Read more about SIGA Technologies, Inc. Reports Financial Results for Fiscal Year 2019
SIGA Announces Collaboration with Turnstone Biologics Read more about SIGA Announces Collaboration with Turnstone Biologics
SIGA to Host Business Update Call on March 5, 2020 after Release of Year End Financial Results Read more about SIGA to Host Business Update Call on March 5, 2020 after Release of Year End Financial Results
SIGA Announces Canadian Department of National Defence Intent to Purchase Up To 15,325 Courses of Oral TPOXX® Read more about SIGA Announces Canadian Department of National Defence Intent to Purchase Up To 15,325 Courses of Oral TPOXX®
SIGA Announces Canadian Release of the Advanced Contract Award Notice to Support Regulatory Filing for Oral TPOXX® Read more about SIGA Announces Canadian Release of the Advanced Contract Award Notice to Support Regulatory Filing for Oral TPOXX®
SIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019 Read more about SIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019
SIGA Completes Clinical Studies for IV Formulation of TPOXX®, NDA to be Submitted in 2020 Read more about SIGA Completes Clinical Studies for IV Formulation of TPOXX®, NDA to be Submitted in 2020